Hypersensitivity syndrome reactions to antiepileptic drugs, clinical characteristic and association with HLA-B * 1502

National Medical Journal of China

Volumn 90, Issue 39, 2010, Pages 2763-2766

  Sun, Dan ^a   Shi, Yi Wu ^b   Liu, Zhi Sheng ^b   Liao, Wei Ping ^a   Wang, Fang Lin ^a   Wu, Ge Fei ^a   Hu, Jia Sheng ^a   He, Cai Ying ^a  

^a Wuhan Children's Hospital   (China)

^b NONE

Author keywords

Anticonvulsants; Gene; HLA B * 1502; Hypersensitive syndrome

Indexed keywords

CARBAMAZEPINE; HLA B ANTIGEN; OXCARBAZEPINE; PHENOBARBITAL; ANTICONVULSIVE AGENT;

ARTICLE; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DRESS SYNDROME; FEVER; GENOTYPE; HUMAN; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; STEVENS JOHNSON SYNDROME; CHILD; DRUG HYPERSENSITIVITY; EPILEPSY; FEMALE; GENETICS; IMMUNOLOGY; INFANT; MALE; PRESCHOOL CHILD;

ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; EPILEPSY; FEMALE; HLA-B ANTIGENS; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES;

EID: 84871408212     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2010.39.007     Document Type: Article

References (13)

1. Griffin J W, Li C Y, Hon I V, et al, Guillain-Barré syndrome innorthern China; the spectrum of neuropathological changes inclinically defined cases. Brain, 1995, 118: 577-595.
2. Roujeau J C. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis; a clinical classification. J Invest Dermatol, 1994, 102: 28S-30S.
3. Schlienger R G, Shear N H. Antiepileptic drug hypersensitivity syndrome. Epilepsia, 1998, 39 Suppl 7: S3-S7.
4. Nasisbitt D J, Britschgi M, Wong G, et al. Hypersensitivity reactionsto carbamazepine: characterization of the specificity, phenotypeand cytokine profile of drug-specific T cell clones. Mol Pharmaeoi, 2003, 63: 732-741.
5. Nassif A, Beusnssan A, Boumsell L, et al. Toxic epidermalnecrolysis: effector cells ale drug-specific cytotoxic Tceils. J Allergy Clin Lmmunol, 2004, 114: 1209-1215.
6. Hung S I, Chung W H, Jee S H, et al. Gentic susceptibility tocarbamazepine. induced cutaneous adverse drug reactions. Pharmacogenet Genomics, 2006, 16: 297-306.
7. Man C B, Kwan P, Baum L, et al. Association between HLA-B * 1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia, 2007, 48: 1015-1018.
8. Alfirevic A, Jorgensen A L, Williamson P R, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics, 2006, 7: 813-818.
9. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome ethnicity matters. Pharmacogenomics J, 2006, 6: 265-268.
10. Chung W H, Huang S I, Hong H S, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature, 2004, 428: 486.
11. Celeste M, Patrick K, Larry B, et al. Association between HLA-B * 1502 allele and antiepileptic drug-induced cutaneousreactions in ban Chinese. Epilepsia, 2007, 48: 1015-1018.
12. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B * 1502 allele in Thai population. Epilepsia, 2008, 49: 2087-2091.
13. Chen Y C, Chu C Y, Hsiao C H. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B * 1502 genotype. J Euro Acad Dermatol Venereol, 2009, 23: 702-703.